NCT06680089RecruitingPhase 2
CD70-targeted immunoPET Imaging of Kidney Cancer
A Study of the Clinical Application of [18F]RCCB6 PET/ CT Imaging in the Diagnosis of Kidney Cancer
Source: ClinicalTrials.gov · Last updated 31 Dec 2025
Brief summary (registry, in English)
The aim of this study is to establish and optimize the \[18F\]RCCB6 PET/CT imaging method, and its physiological and pathological distribution characteristics, on the basis of which the diagnostic efficacy of the above imaging agent in renal cancer (especially clear cell renal cell carcinoma) wil be evaluated.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 300 (estimated)
- First submitted
- 6 Nov 2024
- Start date
- 27 Nov 2024
- Primary completion date
- Nov 2026
- Lead sponsor
- RenJi Hospital
- Diseases
- Kidney cancer
- NCT number
- NCT06680089
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 300
- From 27 Nov 2024 to the primary completion date, Nov 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Severe hepatic and renal insufficiency;
- History of serious surgery in the last month;
- Allergic to antibody or single-domain antibody radiopharmaceuticals.
Other
- Pregnancy；
Who the study is looking for
- Aged 18-80 year-old and of either sex；
- Histologically confirmed diagnosis of kidney cancer (especially clear cell renal cell carcinoma and papillary renal cell carcinoma) or suspected kidney cancer by diagnostic imaging;
- Capable of giving signed informed consent, including compliance with the requirements and restrictions listed in the informed consent form (ICF) and this protocol.
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Renji Hospital, School of Medicine, Shanghai Jiao Tong University Coordinator of this site? Confirm its status | Shanghai | China | Recruiting |
Related publications
- CD70-Targeted [18F]RCCB6 Immuno-PET/CT for Diagnosing Clear Cell Renal Cell Carcinoma Metastases: A Prospective Study.J Nucl Med · 2026 · PMID 41381240
This page is information, not medical advice. Discuss any trial with your doctor.